DeuteRx (Oral, Small Molecule Targeted Protein Degradation Portfolio) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

DeuteRx (Oral, Small Molecule Targeted Protein Degradation Portfolio) General Information

Description

Protein degradation portfolio based in Andover, Massachusetts.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Andover, MA
  • United States
Primary Industry
Buildings and Property
Other Industries
Other Pharmaceuticals and Biotechnology
Acquirer
Decoy Therapeutics
Corporate Office
  • Andover, MA
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

DeuteRx (Oral, Small Molecule Targeted Protein Degradation Portfolio) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore DeuteRx (Oral, Small Molecule Targeted Protein Degradation Portfolio)‘s full profile, request access.

Request a free trial

DeuteRx (Oral, Small Molecule Targeted Protein Degradation Portfolio) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore DeuteRx (Oral, Small Molecule Targeted Protein Degradation Portfolio)‘s full profile, request access.

Request a free trial

DeuteRx (Oral, Small Molecule Targeted Protein Degradation Portfolio) FAQs

  • Where is DeuteRx (Oral, Small Molecule Targeted Protein Degradation Portfolio) headquartered?

    DeuteRx (Oral, Small Molecule Targeted Protein Degradation Portfolio) is headquartered in Andover, MA.

  • What industry is DeuteRx (Oral, Small Molecule Targeted Protein Degradation Portfolio) in?

    DeuteRx (Oral, Small Molecule Targeted Protein Degradation Portfolio)’s primary industry is Buildings and Property.

  • Is DeuteRx (Oral, Small Molecule Targeted Protein Degradation Portfolio) a private or public company?

    DeuteRx (Oral, Small Molecule Targeted Protein Degradation Portfolio) is a Private company.

  • What is the current valuation of DeuteRx (Oral, Small Molecule Targeted Protein Degradation Portfolio)?

    The current valuation of DeuteRx (Oral, Small Molecule Targeted Protein Degradation Portfolio) is .

  • What is DeuteRx (Oral, Small Molecule Targeted Protein Degradation Portfolio)’s current revenue?

    The current revenue for DeuteRx (Oral, Small Molecule Targeted Protein Degradation Portfolio) is .

  • Who are DeuteRx (Oral, Small Molecule Targeted Protein Degradation Portfolio)’s investors?

    DeuteRx has invested in DeuteRx (Oral, Small Molecule Targeted Protein Degradation Portfolio).

  • When was DeuteRx (Oral, Small Molecule Targeted Protein Degradation Portfolio) acquired?

    DeuteRx (Oral, Small Molecule Targeted Protein Degradation Portfolio) was acquired on 13-Jan-2022.

  • Who acquired DeuteRx (Oral, Small Molecule Targeted Protein Degradation Portfolio)?

    DeuteRx (Oral, Small Molecule Targeted Protein Degradation Portfolio) was acquired by Decoy Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process